

# Financial Tear Sheet

## Corporate Profile

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by avoiding unwanted immune responses. Selecta's tolerogenic Synthetic Vaccine Particles (SVPT™) technology platform is designed to enable a range of novel biologics for rare and serious diseases that require new treatment options. The company's current proprietary pipeline includes SVP-enabled enzyme, oncolo... [View more »](#)

## Primary IR Contact

**Selecta Biosciences**  
 Jason Fredette  
 Phone: 1 617 231 8078  
 E-mail: [JFredette@selectabio.com](mailto:JFredette@selectabio.com)

## Stock Information

SELB (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	<b>\$18.05</b>
Change (%)	<span style="color: green;">▲ 0.77 (4.46%)</span>
Volume	44,195
52 Week High	\$28.00
52 Week Low	\$10.26
Market Cap	\$321,083,171
Rolling EPS	-4.76
PE Ratio	0
Shares Outstanding	18,581,202



Data as of Jul 24, 2017 4:00 p.m. ET

## Recent News

Jun 26, 2017

[Selecta Biosciences Announces \\$50 Million Private Placement](#)

---

Jun 19, 2017

[Selecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors](#)

---

Jun 15, 2017

[Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout](#)

---

## SEC Filings

Filing Date	Form
Jul 21, 2017	<a href="#">EFFECT</a>
Jul 13, 2017	<a href="#">S-3</a>
Jul 11, 2017	<a href="#">D</a>
Jul 11, 2017	<a href="#">4</a>

## Upcoming Events

There are currently no events scheduled.

## Corporate Governance

<a href="#">Werner Cautreels, Ph.D.</a>	President and CEO
<a href="#">Lloyd Johnston, Ph.D.</a>	Chief Operating Officer and Senior Vice President Research and Development
<a href="#">Takashi Kei Kishimoto, Ph.D.</a>	Chief Scientific Officer
<a href="#">Peter Keller, M.Sci.</a>	Chief Business Officer
<a href="#">David Abraham, J.D.</a>	General Counsel and Corporate Secretary
<a href="#">Earl Sands, M.D.</a>	Chief Medical Officer
<a href="#">David Siewers</a>	Chief Financial Officer
<a href="#">Dmitry Ochinnikov, Ph.D.</a>	Managing Director, SelectaRUS, LLC

Data provided by Nasdaq. Minimum 15 minutes delayed.